Diagnostic associations of gene expression signatures in prostate cancer tissue

Current Opinion in Urology

Volumn 25, Issue 1, 2015, Pages 65-70

  Nguyen, Hao G ^a   Welty, Christopher J ^a   Cooperberg, Matthew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Gene expression profile; Prostate cancer; Risk stratification

Indexed keywords

ABIRATERONE; BIOLOGICAL MARKER; ENZALUTAMIDE; MICRORNA; TRANSCRIPTOME; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL PRACTICE; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; METASTASIS; OVERALL SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; SOMATIC MUTATION; TISSUE SECTION; DISEASE COURSE; MALE; METABOLISM; PROSTATIC NEOPLASMS;

DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84918547773     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000131     Document Type: Review

References (43)

1. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014; 12:686-718.
2. Thompson I, Thrasher JB, Aus G, et al. Guideline for themanagement of clinically localized prostate cancer: 2007 update. J Urol 2007; 177:2106-2131.
3. McKenney JK, Simko J, Bonham M, et al. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: A multi institutional study. J Urol 2011; 186:465-469.
4. Sartori DA, Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol 2014; 26:259-264.
5. Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 2012; 9:652-664.
6. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23:9067-9072.
7. Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. J Natl Cancer Inst 2008; 100:1432-1438.
8. Gulati R, Tsodikov A, Wever EM, et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012; 23:827-835.
9. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or 1/44.0 ng per milliliter. N Engl J Med 2004; 350:2239-2246.
10. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014. [Epub ahead of print].
11. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185:1650-1655.
12. Lazzeri M, Haese A, Abrate A, et al. Clinical performance of serum pros tate specific antigen isoform [-2]pro PSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROME theu S project. BJU Int 2013; 112:313-321.
13. Nordstrom T, Vickers A, Assel M, et al. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol 2014. [Epub ahead of print].
14. Stephan C, Vincendeau S, Houlgatte A, et al. Multicenter evaluation of [-2]pro prostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 2013; 59:306-314.
15. Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011; 20:255-261.
16. Day JR, Jost M, Reynolds MA, et al. PCA3: from basic molecular science to the clinical lab. Cancer Lett 2011; 301:1-6.
17. Trock BJ, Brotzman MJ, Mangold LA, et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 2012; 110:56-62.
18. Troyer DA, Lucia MS, de Bruine AP, et al. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev 2009; 18:2717-2722.
19. Stewart GD, Van Neste L, Delvenne P, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol 2013; 189:1110-1116.
20. Partin AW, Van Neste L, Klein EA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol 2014; 192:1081-1087.
21. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011; 29:3669-3676.
22. Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012; 106:1095-1099.
23. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol 2011; 12:245- 255.
24. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013; 31:1428-1434.
25. Arsov C, Jankowiak F, Hiester A, et al. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy: A pilot study. Anticancer Res 2014; 34:2459-2466.
26. Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 2014; 192:409-414.
27. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multi focality, and biopsy under sampling. Eur Urol 2014; 66:550- 560.
28. Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Onco type DX prostate cancer assay: A clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 2013; 14:690.
29. Van den Bergh RC, Ahmed HU, Bangma CH, et al. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: A systematic review. Eur Urol 2014; 65:1023-1031.
30. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013; 8:e66855.
31. Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013; 190:2047-2053.
32. Cooperberg MR, Davicioni E, Crisan A, et al. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2014. [Epub ahead of print].
33. Cullen IR J, Brand T, Ali A, et al. A prospectively-designed study to determine the association of a 17-gene genomic prostate score with recurrence following surgery for localised prostate cancer (PCa). ESMO 2014 2014 (Abstract: LBA22 European Society of Medical Oncology Annual Conference).
34. Levin AM, Lindquist KJ, Avila A, et al. Performance of the genomic evaluators of metastatic prostate cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients. Cancer Epidemiol Biomarkers Prev 2014; 23:1677-1682.
35. Kattan MW. Evaluating a marker's contribution to a nomo gram: The GEM CaP example. Clin Cancer Res 2010; 16:1-3.
36. Paris PL, Weinberg V, Albo G, et al. A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with highrisk prostate cancer. Clin Cancer Res 2010; 16:195-202.
37. Wang SY, Shiboski S, Belair CD, et al. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One 2014; 9:e98597.
38. Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation anti androgens enzalutamide and ARN-509. Can Discov 2013; 3:1020-1029.
39. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371:1028- 1038.
40. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302-6309.
41. Friedlander TW, Roy R, Tomlins SA, et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 2012; 72:616-625.
42. Shore N, Concepcion R, Saltzstein D, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin 2014; 30:547-553.
43. Michalopoulos SN, Kella N, Payne R, et al. Influence of a genomic classifier on postoperative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study. Curr Med Res Opin 2014; 30:1547-1556.